Bijan Boldajipour

Bijan Boldajipour has extensive work experience in the field of immunotherapy and cancer research. Bijan began their career at the Max Planck Institute for Biophysical Chemistry as a Graduate Student from 2005 to 2009. Bijan then worked as a Postdoctoral Fellow and Graduate Student at the University of Muenster from 2008 to 2010, where they focused on studying cellular signaling circuits in immune responses.

In 2010, Boldajipour joined the University of California, San Francisco (UCSF) as a Postdoctoral Fellow, exploring immune cell interactions in breast cancer and their potential for targeted immunotherapy. From 2011 to 2015, they served as the Campus Chair at UCSF for the UAW Local 5810, organizing the Postdoctoral Union and representing their interests.

Boldajipour joined Pfizer in 2015 as a Senior Scientist, later becoming a Principal Scientist in 2016. During their time at Pfizer, they supervised a team working on T cell-based therapies for cancer, including chimeric antigen receptor T cell and bispecific antibody technologies. Bijan also led a clinical CART program, managing research and external collaborations.

In 2018, Boldajipour joined Kite Pharma as a Director of Technology Development, and in 2019, they moved to Lyell Immunopharma as a Senior Director. At Lyell, they played a key role in establishing the company's research labs, leading the development of T cell projects and studying their mechanism of action in clinical trials.

Throughout their career, Boldajipour has demonstrated expertise in immunotherapy research, strategic decision-making, team leadership, and regulatory compliance.

Bijan Boldajipour completed their Bachelor of Science (BSc) in Molecular Biotechnology from Universität zu Lübeck. Bijan then pursued further education and obtained a Doctor of Philosophy (Ph.D.) in Molecular Biology from The University of Göttingen.